MENLO PARK, Calif.,
June 30, 2023 /PRNewswire/
-- Gamma Biosciences, a life sciences platform created by
global investment firm KKR to address the advanced therapy
bioprocessing market, today announced that its operating company,
Univercells Technologies ("UT"), a leading provider of novel
biomanufacturing technologies for flexible and scalable advanced
therapies and vaccine production, has been acquired by Donaldson
Company, Inc. (NYSE: DCI).
Donaldson is a leading worldwide provider of innovative
filtration products and solutions. The deal follows several recent
acquisitions by Donaldson in the field of bioprocessing, including
Solaris Biotechnology, Purilogics and Isolere Bio. UT's single-use
bioreactor systems and integrated biomanufacturing platforms,
focused on the production of viruses used in cell and gene therapy,
viral vaccines and other therapeutics, will add to Donaldson's
growing offering in life sciences.
"I am proud of the achievements of our team during this journey
with Univercells and Gamma Biosciences, as we ramped-up our
development, production and service capabilities and continued to
innovate and launch novel products," said Mathias Garny, CEO of UT. "We are now looking
forward to this new era with Donaldson to further strengthen our
market position and deliver robust, end-to-end biomanufacturing
solutions to our customers as they advance towards
commercialization of advanced therapies and vaccines."
"We are delighted that UT will join Donaldson as it expands its
presence in biomanufacturing, leveraging its legacy of filtration
technology leadership" said Matt
Gunnison, CEO of Gamma Biosciences. "UT has developed a
best-in-class platform for efficient manufacturing of gene
therapies and vaccines and will be well positioned as part of the
larger Donaldson organization to support the market going
forward."
Gamma Biosciences first invested in UT in June 2020 and has worked closely with the company
to fund the development, manufacture and commercialization of the
scale-X™ and NevoLine™ product
lines, which are based on the company's novel structured, fixed-bed
design for high-density adherent and suspension cell culture.
According to the terms of the transaction, Donaldson acquired
all outstanding shares of the business from Gamma and its fellow
shareholder, Univercells SA, for approximately €136M in cash net of
debt. Rothschild & Co acted as financial advisor to Univercells
Technologies. Sidley Austin LLP and Freshfields Bruckhaus
Deringer US LLP acted as legal advisors to Gamma and
Univercells, respectively.
About Gamma Biosciences
Gamma Biosciences is a life
sciences tools platform created by KKR. Gamma's mission is to
support leading players in next-generation bioprocessing for
advanced therapies by acquiring or investing in high-potential
businesses with outstanding technology and accelerating their
growth.
About Donaldson Company, Inc.
Founded in 1915,
Donaldson (NYSE: DCI) is a global leader in technology-led
filtration products and solutions, serving a broad range of
industries and advanced markets. Our diverse, skilled employees at
over 140 locations on six continents partner with customers—from
small business owners to the world's biggest OEM brands—to solve
complex filtration challenges. Discover how Donaldson is Advancing
Filtration for a Cleaner World at www.Donaldson.com.
About Univercells Technologies
Univercells
Technologies is a global provider of innovative biomanufacturing
technologies to achieve cost-effective advanced therapies and
vaccines production from R&D to commercial scales. The Company
offers a comprehensive technology portfolio leveraging the
strengths of process intensification and chaining as a direct
answer to the growing demand of viral vectors and viral vaccines.
Univercells Technologies is committed to helping customers increase
performance with minimized footprint and costs today, while
anticipating the needs of tomorrow.
Logo -
https://mma.prnewswire.com/media/1295160/Gamma__Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/univercells-technologies-acquired-by-donaldson-company-301867767.html